tiprankstipranks

CareDx Announces Strong Revenue Growth and Outlook

Story Highlights
CareDx Announces Strong Revenue Growth and Outlook

An announcement from CareDx ( (CDNA) ) is now available.

CareDx announced its preliminary financial results for the fourth quarter and full year of 2024, highlighting a significant 30% year-over-year revenue growth in the fourth quarter and a full-year revenue projection between $332 million to $333 million. The company anticipates strong growth in 2025 with expected revenue of $370 million, supported by the expansion of its sales and marketing team and continued momentum in kidney surveillance testing. Despite a projected GAAP loss, CareDx achieved positive adjusted EBITDA, indicating operational efficiency and financial health improvements.

More about CareDx

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

YTD Price Performance: 9.80%

Average Trading Volume: 797,435

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $1.27B

See more insights into CDNA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App